Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2020-03-20 Director's Dealing
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2020-03-20 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement (a Master Services Agreement and related Work Order) with Covance Inc. It includes details about the agreement terms and references exhibits attached. There are no financial statements or quarterly/yearly financial results presented. The document is not an annual or interim report, earnings release, or management discussion. It is a regulatory filing announcing a material contract event. Therefore, it fits best under Regulatory Filings (RNS). The document length is 4711 characters, which is short and consistent with an 8-K announcement rather than a full report.
2020-03-17 English
FORM 4 SUBMISSION
Director's Dealing
2020-03-16 English
FORM 3 SUBMISSION
Director's Dealing
2020-03-16 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 16, 2020, by Galectin Therapeutics Inc. It announces the issuance of a press release regarding the company's results of operations and financial condition for the year ended December 31, 2019. The document explicitly states that it is furnishing information pursuant to Item 2.02 of Form 8-K, which relates to Results of Operations and Financial Condition. The document includes a press release as an exhibit but does not contain detailed financial statements or substantive financial data itself. It is a current report announcing financial results rather than the full annual report or earnings release. Given the nature of the filing and the content, this is best classified as a Regulatory Filing (RNS), as it is a general regulatory announcement and does not contain the full financial report or detailed financial data itself.
2020-03-16 English
FORM 10-K
Annual Report FY 2019
2020-03-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.